2795 Participants Needed

Disease Burden Assessment for Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

(MEASUREAAVitHS Trial)

Recruiting at 87 trial locations
BR
Overseen ByBeth Rycroft
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: AbbVie
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand how living with conditions like alopecia areata (patchy hair loss), vitiligo (loss of skin color in patches), and hidradenitis suppurativa (painful skin lumps) affects daily life. Researchers seek insights from individuals with moderate to severe forms of these conditions. Those diagnosed by a doctor with any of these conditions and able to complete study questionnaires might be a good fit for the study.

As an unphased trial, this study offers a unique opportunity to contribute valuable insights that could enhance understanding and management of these conditions.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to understand the disease burden of alopecia areata, vitiligo, and hidradenitis suppurativa. Unlike treatments that focus solely on managing symptoms, this trial seeks to gather comprehensive data on how these conditions impact patients' quality of life. This approach can lead to more targeted therapies and improved patient care by highlighting unmet needs and areas for therapeutic innovation. By focusing on the overall impact of these conditions, the trial has the potential to guide future treatments that are more effective and patient-centered.

Who Is on the Research Team?

AI

ABBVIE INC.

Principal Investigator

AbbVie

Are You a Good Fit for This Trial?

Inclusion Criteria

I can understand study questionnaires, with help if I'm a teenager.
I have been diagnosed with NSV, moderate to severe AA, or moderate to severe HS by a doctor.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Assessment

Participants' quality of life and disease severity are assessed using various scales such as DLQI, AASIS, SALT, F-VASI, VitiQoL, and IHS4

Up to Day 1

Follow-up

Participants are monitored for any changes in quality of life and disease severity after initial assessment

4 weeks

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

AbbVie

Lead Sponsor

Trials
1,079
Recruited
535,000+
Founded
2013
Headquarters
North Chicago, USA
Known For
Immunology treatments
Top Products
Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael profile image

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois